Companies /Healthcare
Pfizer Inc
NYSE: PFE Drug Manufacturers - General
$27.51
▼ $0.55 (−1.95%) today
Markets open · 3:23pm ET

Pfizer (PFE) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
PFE vs Market · 30-day return after each reportPFES&P 500
−6%0%+6%+12%−6.8%−0.6%Q4 22−1.3%+6.3%Q1 25+0.5%+3.1%Q2 25+7.1%+1.6%Q3 25+5.0%−2.5%Q4 25−1.6%+1.9%Q1 26+13.4%+0.2%Q2 26
−6%0%+6%+12%Q4 22Q2 25Q4 25Q2 26
PFE EPS Trend · estimate vs actualEstimateActual
$0.00$0.40$0.80$1.20$1.04$1.14Q4 22$0.67$0.92Q1 25$0.57$0.78Q2 25$0.63$0.87Q3 25$0.57$0.66Q4 25$0.52$0.75Q1 26$0.68$0.77Q2 26$0.73$0.87Q3 26
$0.00$0.40$0.80$1.20Q4 22Q2 25Q4 25Q2 26
PFE Revenue Trend · estimate vs actualEstimateActual
$0$7.0B$14.0B$21.0B$24.3B$24.3BQ4 22$14.1B$13.7BQ1 25$13.5B$14.7BQ2 25$16.5B$16.7BQ3 25$16.9B$17.6BQ4 25$13.8B$14.5BQ1 26$14.4B$15.0BQ2 26$15.9B$16.6BQ3 26
$0$7.0B$14.0B$21.0BQ4 22Q2 25Q4 25Q2 26

How Often Does Pfizer Beat Earnings Estimates?

Pfizer beat EPS estimates in 8 of its last 8 reported quarters, and has beaten 8 quarters in a row.

PFE quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q3 2026 Adjusted results include a one-time $650 million Acquired In-Process R&D charge related to the Innovent Biologics in-licensing and collaboration agreement (approximately $0.10 unfavorable impact). GAAP diluted EPS of $0.56 additionally reflects $1,128 million amortization of intangible assets and $791 million restructuring charges and certain acquisition-related costs. $0.87 est. $0.73 +19.51% $16.6B est. $15.9B +4.45%
Q2 2026 $0.77 est. $0.68 +12.87% $15.0B est. $14.4B +4.49%
Q1 2026 $0.75 est. $0.52 +44.23% $14.5B est. $13.8B +4.70%
Q4 2025 $0.66 est. $0.57 +15.79% $17.6B est. $16.9B +4.09%
Q3 2025 $0.87 est. $0.63 +38.10% $16.7B est. $16.5B +0.92%
Q2 2025 $0.78 est. $0.57 +36.84% $14.7B est. $13.5B +8.29%
Q1 2025 $0.92 est. $0.67 +37.31% $13.7B est. $14.1B −2.69%
Q4 2022 $1.14 est. $1.04 +9.62% $24.3B est. $24.3B +0.02%

Figures from SEC filings and company reports. Not investment advice.